[Edaily Reporter Kim Hyung-il ] As concerns over a resurgence of COVID-19 grow, shares of COVID-19 vaccine developer Cellid Co., Ltd.(299660)are surging by more than 20% in early trading. With buying interest flowing into COVID-19-related stocks across the board, investor attention is also focusing on Cellid Co., Ltd.

According to MP Doctor on the 24th, as of 9:33 a.m., Cellid Co., Ltd. is trading at 2,155 won, up 402 won (22.58%) from the previous trading day. In early trading today, the stock surged as high as 22,850 won—a 30% increase from the previous trading day—hitting the daily price limit.

With concerns over a resurgence of COVID-19 coming back into focus recently, stocks related to vaccines and treatments are showing strong performance. Cellid Co., Ltd. is a biotech company that has been developing a COVID-19 vaccine, utilizing its proprietary adenovirus vector platform.

Its main pipeline candidate, “AdCLD-CoV19-1 OMI,” is a COVID-19 preventive vaccine developed to target the Omicron variant. Cellid Co., Ltd. conducted a global Phase 3 clinical trial for this vaccine; however, results announced last June showed that it did not meet the non-inferiority criteria for the primary immunogenicity endpoint compared to the control vaccine. Nevertheless, in terms of safety, it met the previously established safety profile, with no serious adverse drug reactions reported.

Based on these clinical results, Cellid Co., Ltd. is reviewing the design of additional clinical trials and its development strategy. The company plans to continue leveraging its existing adenovirus vector platform to develop vaccines for infectious diseases, including COVID-19.